Roundview Capital’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Sell |
34,871
-1,533
| -4% | -$72.6K | 0.08% | 195 |
|
|
2025
Q4 | $1.85M | Sell |
36,404
-2,776
| -7% | -$142K | 0.11% | 159 |
|
|
2025
Q3 | $2.17M | Sell |
39,180
-12,337
| -24% | -$722K | 0.14% | 140 |
|
|
2025
Q2 | $3.56M | Sell |
51,517
-4,902
| -9% | -$333K | 0.24% | 99 |
|
|
2025
Q1 | $3.92M | Buy |
56,419
+1,681
| +3% | +$139K | 0.28% | 83 |
|
|
2024
Q4 | $4.71M | Buy |
54,738
+5,396
| +11% | +$584K | 0.33% | 71 |
|
|
2024
Q3 | $5.88M | Buy |
49,342
+559
| +1% | +$74.5K | 0.43% | 56 |
|
|
2024
Q2 | $6.96M | Sell |
48,783
-995
| -2% | -$132K | 0.55% | 40 |
|
|
2024
Q1 | $6.39M | Buy |
49,778
+231
| +0.5% | +$27.5K | 0.52% | 45 |
|
|
2023
Q4 | $5.13M | Sell |
49,547
-871
| -2% | -$86.1K | 0.47% | 49 |
|
|
2023
Q3 | $4.59M | Sell |
50,418
-1,848
| -4% | -$163K | 0.46% | 53 |
|
|
2023
Q2 | $4.23M | Sell |
52,266
-54
| -0.1% | -$4.41K | 0.41% | 59 |
|
|
2023
Q1 | $4.16M | Buy |
52,320
+2,114
| +4% | +$150K | 0.44% | 64 |
|
|
2022
Q4 | $3.4M | Buy |
50,206
+994
| +2% | +$58.3K | 0.39% | 75 |
|
|
2022
Q3 | $2.45M | Buy |
49,212
+11,846
| +32% | +$635K | 0.31% | 88 |
|
|
2022
Q2 | $2.08M | Sell |
37,366
-240
| -0.6% | -$13.3K | 0.25% | 105 |
|
|
2022
Q1 | $2.09M | Buy |
37,606
+212
| +0.6% | +$10.9K | 0.21% | 117 |
|
|
2021
Q4 | $2.09M | Sell |
37,394
-332
| -0.9% | -$18K | 0.21% | 123 |
|
|
2021
Q3 | $1.81M | Buy |
37,726
+52
| +0.1% | +$2.51K | 0.2% | 128 |
|
|
2021
Q2 | $1.58M | Buy |
37,674
+806
| +2% | +$31.2K | 0.18% | 136 |
|
|
2021
Q1 | $1.24M | Buy |
36,868
+868
| +2% | +$30.9K | 0.16% | 146 |
|
|
2020
Q4 | $1.26M | Buy |
36,000
+94
| +0.3% | +$3.25K | 0.17% | 135 |
|
|
2020
Q3 | $1.25M | Buy |
35,906
+394
| +1% | +$13.1K | 0.2% | 119 |
|
|
2020
Q2 | $1.16M | Sell |
35,512
-1,464
| -4% | -$46.7K | 0.2% | 119 |
|
|
2020
Q1 | $1.11M | Buy |
36,976
+1,488
| +4% | +$44.3K | 0.24% | 114 |
|
|
2019
Q4 | $1.03M | Buy |
35,488
+712
| +2% | +$19.7K | 0.2% | 137 |
|
|
2019
Q3 | $899K | Buy |
34,776
+200
| +0.6% | +$5.06K | 0.19% | 138 |
|
|
2019
Q2 | $882K | Buy |
34,576
+1,356
| +4% | +$33.5K | 0.2% | 131 |
|
|
2019
Q1 | $869K | Sell |
33,220
-520
| -2% | -$12.8K | 0.21% | 126 |
|
|
2018
Q4 | $777K | Buy |
33,740
+420
| +1% | +$9.33K | 0.22% | 119 |
|
|
2018
Q3 | $785K | Buy |
33,320
+440
| +1% | +$10.7K | 0.19% | 135 |
|
|
2018
Q2 | $758K | Buy |
32,880
+2,330
| +8% | +$55.4K | 0.2% | 134 |
|
|
2018
Q1 | $752K | Buy |
30,550
+600
| +2% | +$15.8K | 0.21% | 127 |
|
|
2017
Q4 | $804K | Hold |
29,950
| – | – | 0.21% | 126 |
|
|
2017
Q3 | $721K | Sell |
29,950
-29,986
| -50% | -$678K | 0.21% | 126 |
|
|
2017
Q2 | $1.28M | Buy |
+59,936
| New | +$1.21M | 0.37% | 85 |
|
Other funds holding NVO
DAM
F
Roundview Capital's NVO Position: Q1 2026 in Review
Roundview Capital reduced its Novo Nordisk (NVO) stake by 4.2% in Q1 2026, selling an estimated $72.6K and leaving 34,871 shares worth $1.28M. The position accounts for 0.08% of the portfolio, ranked #195.
Roundview Capital first reported a position in NVO in Q2 2017 and has held it in 36 quarters since. The position peaked at $6.96M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Roundview Capital held 34,871 shares of Novo Nordisk worth $1.28M as of Q1 2026.
- Roundview Capital sold 1,533 Novo Nordisk shares in Q1 2026, an estimated $72.6K.
- Novo Nordisk made up 0.08% of Roundview Capital's portfolio in Q1 2026, its #195 holding.
- Roundview Capital first reported a position in Novo Nordisk in Q2 2017 and has held it in 36 quarters since.
- Roundview Capital's Novo Nordisk position peaked at $6.96M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.